The setback leaves Lilly and partner Hanmi Pharmaceutical to weigh whether it is worth moving the Bruton's TKI forward in other indications.

CRISPR is a promising treatment for blood disorders, but it comes with challenges, such as off-target effects.

The FDA has issued a complete response letter for Apricus’ topical ED drug Vitaros again, sparking a massive after-hours slump in its share price.

The takeover gives Roche ownership of the cancer software and real-world evidence that turned GV-backed Flatiron into a rising star.

Scientists at Stanford University believe stem cells can teach the immune system to recognize and attack cancer.

Roivant and Arbutus have a month to decide if they're going to set up a new company for RNA delivery.

A Celgene spinout known as Celularity with some of the biggest names in biotech and Silicon Valley has raised $250 million for its work in cancer.

Vertex Pharma now has a pair of studies backing up its new drug VX-150, suggesting it can provide opioidlike pain relief without the addiction risks.

The Swiss biotech penned a CHF 127.5 million ($138 million) deal for the human neutrophil elastase inhibitor to expand its clinical pipeline.